Our Key Takeaways from Fierce Pharma Week

At The HWP Group, we pay close attention to these industry trends because they reflect the daily challenges we help our clients solve. Here are our biggest takeaways from our time at Fierce Pharma Week:

AI Has Moved from Research and Development to HCP Engagement

AI has already transformed drug discovery and trial design, but the conversations at Fierce show how quickly it's moving to the HCP. Companies are now:

• Testing marketing messages against AI-generated competitor personas
• Using chat-based personas to simulate HCP responses
• Feeding research transcripts into large language models to uncover insights faster

The promise is obvious: more immediate insights, cost savings, and agility; but the challenge also is clear. Fewer than a third of us feel confident using these AI tools. Without cultural readiness, governance, and human oversight, AI can create more risk than reward.

AI works best when it accelerates credible HCP communication. We must use it to enrich strategy, stress-test content, and create efficiency while maintaining compliance and trust.

Omnichannel Requires Storytelling, Not Saturation

Many companies still conflate omnichannel with "be everywhere." That simplistic approach can create disjointed touchpoints, burn out teams, and leave HCPs cold. What works is more disciplined:

• Pilots and fail-fast strategies to test what fits into workflows
• Modular content that can flex across channels and formats
• Integrated storytelling that ensures consistency across live, digital, and on-demand presentations

At Fierce, presenters emphasized that the "shiny tools" don't matter if the story isn't coherent. We must build compliant ecosystems designed to simplify and streamline development.

Key Opinion Leader (KOL) and HCP Engagement Is Still Too Fragmented

A frustration emphasized at Fierce was teams duplicating HCP outreach efforts and missing chances to deepen trust, while not making use of company-wide insights blocked by internal silos. Imagine setting up a meeting with a KOL only to find another team from your company spoke with them the day before. Lack of coordination erodes credibility.

Platforms such as HWP Engage exist to unify external data (i.e. publications, congress activity) with internal data (i.e. customer relationship management, trial participation), creating a 360-degree view of KOL engagement. Unfortunately, adoption lags, and the real issue is often cultural, not technological.

KOL engagement must be organized, strategic, and comprehensive. We must build relationships, integrate insights, and ensure every touchpoint adds value. When done right, KOL engagement builds credibility that cascades across an entire organization.

Measurement Must Shift from Vanity to Impact

Clicks, downloads, and post-presentation survey responses are easy to tally but don't always prove impact. At Fierce, the conversation shifted toward:

• Did the scientific dialogue move forward?
• Did HCPs walk away with clarity that influences decision-making?
• Did behavior change in clinical practice?

The future of measurement is about outcomes, not activity. We must build measurement frameworks that tell a story, not just fill a dashboard. Quantitative data must be supplemented with qualitative insights to bring more power to our initiatives.

Closing Thoughts

Fierce made one thing clear: the gap between ambition and execution is still fairly wide. Winning companies will pair innovation with credibility by delivering content that matters, in formats that resonate, at the moments that count. At The HWP Group, that continues to be our goal.